Individualized cancer chemotherapy

2^nd World Congress on Biomarkers & Clinical Research

12-14 September 2011 Baltimore, USA

Da-Yong Lu and Ting Ren Lu

Scientific Tracks Abstracts: J Mol Biomark Diagn

Abstract :

A major obstacle to control cancer growth and metastasis in patients is the widespread inappropriate use of anticancer drugs. As increasing numbers and types of anticancer drugs has been developed, clinicians become more and more likely to misuse them in their practice. We have known that cancers are diff erent etiological diseases with the same pathologic characteristics of unlimited growths. With this type of heterogenous characters, it means responses to same anticancer drugs can be various from patient to patient even though they all develop from same organs of humans, or even represent with same histological tissues or phenotype. Owing to all these reasons, individualized cancer chemotherapy will be a future trend to improve the anticancer drug applications in clinics. In this article, we will document, review, discuss and highlight this issue.

Biography :

LU Da-Yong, oc/professor; ad/1288 Shangda Rd, 95-202, Shanghai200444, PR China; ed/ph D Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2005, MS, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1986, BS, Shanghai Medical University (Now Fudan University affi liated),1982; Now School of Life Sciences, Shanghai University, Shanghai200444, PR China. Undergo the studies of cancer pathology, biochemistry pharmacology and clinical therapeutics from 1982 and some hypotheses in AIDS and neural science in 2007. More than 20 scientifi c articles have been published in international journals.